Antibodies
25 February 2014
Lilly’s Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes24 February 2014
VALNEVA Initiates Fourth Antibody Discovery Program for Sanofi Pasteur on its VivaScreen® Platform24 February 2014
NBE-Therapeutics Announces Successful Validation of its SMAC™-Technology for the Generation of Antibody Drug Conjugates (ADCs)19 February 2014
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival18 February 2014
OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Sorafenib (Nexavar(R)) in Hepatocellular Cancer18 February 2014
CytoDyn Submits Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV18 February 2014
Preclinical Study Results of Merrimack’s MM-141 Published in Molecular Cancer Therapeutics14 February 2014
GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis13 February 2014
Alvogen launches Inflectra in Europe with Hospira5 February 2014
Seattle Genetics Achieves Sales Milestone Under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda5 February 2014
Elusys Completes Enrollment in Three Phase 3 Safety Studies of Its Anthrax Anti-Toxin, ETI-204, in Adult Volunteers4 February 2014
TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients With Advanced Soft Tissue Sarcoma3 February 2014
Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS72130 January 2014
XBiotech and European Medicines Agency (EMA) Agree on Phase III Registration Study for Treatment of Colorectal Cancer25 January 2014
CHMP recommends EU approval of a new formulation of Roche’s MabThera for patients with non-Hodgkin lymphoma23 January 2014
The exponential growth of the field of antibody-drug conjugates provides plenty of business opportunities22 January 2014
Kolltan Pharmaceuticals Initiates Phase 1 Study of KTN3379, A Dual-Mechanism Anti-ErbB3 Monoclonal AntibodyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports